S64
29.9.2022 14:40:15 CEST | Business Wire | Press release
S64, the trusted alternatives partner to the world’s leading asset managers and private banks, has today announced a series of strategic hires following a period of rapid growth since its launch in 2020.
S64’s best-in-class team, who worked together for over a decade at Deutsche Bank, has further strengthened its expertise by making a number of appointments from blue-chip institutions to its London office. The business also has plans to advance its footprint across EMEA, Asia and Australia in major global financial hubs.
Strategic hires following rapid growth
Led by founder and CEO Tarun Nagpal, S64’s team has led the way in industry innovation for more than a decade, pioneering the development of alternative platform solutions. The latest additions include Venkata Kota, Head of Client Solutions, formerly of Goldman Sachs and Deutsche Bank; Richard Marland, Head of Operations and Fund Governance, formerly of Deutsche Bank; Tetyana Turek, Business and Project Management, formerly of Deutsche Bank; Mark Slater, Legal Counsel and Compliance, formerly of J.P. Morgan and Simmons & Simmons; and Eve Wachtel, Asia Pacific Distribution, formerly of Deutsche Bank.
The firm’s structuring and solutions team also boasts three new additions, comprising Matteo De Checchi, Dennis Bews and Adam Hooper, from Deutsche Bank, Credit Suisse and Barings respectively.
S64 expects to more than double its 40-strong headcount over the next 12 months across its structuring, distribution, platform and technology expertise.
Tarun Nagpal, CEO of S64, commented: “I’m delighted to welcome some of the industry’s leading talent to our firm. Not only do they bring with them deep technical experience, but a track record of market-defining innovation.
We are witnessing a revolution in how private markets are accessed. Our award-winning legacy, unique proposition and market-leading expertise mean we are well-positioned to build upon our impressive growth to date.
As we define a new era in alternative assets, we plan to deepen our expertise through further strategic hires and expand our presence into target markets over the coming year.”
Pipeline of mandates with platinum-level clients
S64 is already the trusted partner of global leaders across private equity, asset management and private wealth having won numerous competitive mandates, including the majority of the top 10 largest private markets managers globally, who have raised over $750 billion USD of funds in the past decade. The firm has built market share at speed with a robust pipeline of new opportunities.
The business is leading the way in industry innovation through the development of an array of novel solutions for clients, including the structuring, delivery and servicing of ELTIFs, UK LTAFs, and open-ended semi-liquid retail products, helping them rapidly scale their offerings.
Tarun Nagpal added: “We’re excited to be working with platinum-level asset managers and private banks, having won a pipeline of highly-coveted mandates which has turbocharged our ambitious growth trajectory.
With our world-class proprietary technology, which services the full lifecycle of alternatives products, our innovative approach is further opening up access to private markets and enabling them to flourish.”
ENDS.
Notes to Editors
- Global fund manager ranking and fundraising amount according to Preqin’s Fund Managers League Table as of 25.09.22.
- Preqin calculates top global fund managers based on aggregate capital raised via closed-end commingled funds.
- Fundraising amount is based on funds raised in the last 10 years.
About S64
S64 is a leading global alternatives solutions business bridging the opportunity in private markets. It works with the world’s first-class asset managers and private banks across private equity, credit, real estate, infrastructure and impact to develop innovative solutions for private banks and wealth managers.
S64’s innovative technology platform offers the full lifecycle management of alternative assets — from structuring and onboarding to financing, as well as secondary market capabilities.
Its team draws on an award-winning legacy in fund and product solutions, digital innovation and international distribution, having pioneered alternative investment platforms for over a decade.
www.s64capital.com | LinkedIn | Twitter
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220929005482/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom